IDH2 and acute myeloid leukemia: Future research ought to concentrate on the traits of metabolic heterogeneity and employ single-cell metabolomics to thoroughly examine each AML subtype’s metabolic susceptibility (e.g., the regulatory link between IDH mutations and BCAT1 expression).